Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. August 2024 08:30 ET | Quelle: Renexxion LLC

Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient

ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
27. März 2024 08:30 ET | Quelle: Renexxion LLC

Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States

ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
07. Februar 2024 08:00 ET | Quelle: Renexxion LLC

Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories

ROSCREA, Ireland, and FREIBURG, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to...
01. Februar 2024 08:35 ET | Quelle: Renexxion LLC

Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference

ROSCREA, Ireland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
24. Januar 2024 07:00 ET | Quelle: Renexxion LLC

Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD

ROSCREA, Ireland, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
20. Dezember 2023 16:11 ET | Quelle: Renexxion LLC

Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD

ROSCREA, Ireland, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
30. November 2023 07:00 ET | Quelle: Renexxion LLC

Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride

ROSCREA, Ireland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
04. Oktober 2023 07:00 ET | Quelle: Renexxion LLC

Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase

LOS ALTOS, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Renexxion LLC (“Renexxion” or the “Company”), a private clinical-stage biopharmaceutical company committed to delivering innovative drugs to...